Pharma Focus Europe

PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company

Monday, March 06, 2023

Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company. The collaboration will leverage Phanes' proprietary technology platforms, PACbody™ and SPECpair™, in the evaluation of cell therapies in oncology.

Under the terms of the agreement, Phanes will receive a technology access payment and further collaborative research support. The details of the financial terms were not disclosed.

"We are delighted to have the opportunity to collaborate with Xyphos," said Dr. Ming Wang CEO of Phanes. "PACbody™ and SPECpair™ allow construction of native IgG-like bispecific antibodies and production of the molecules using the conventional manufacturing process for monoclonal antibodies. The lead molecule Phanes made using these technologies has entered Phase 1 clinical study. With the bispecific antibody technology platforms we have built, Phanes is well positioned to make important impacts in cell therapies."



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024